Inito has raised $29 million to advance its proprietary antibody engineering platform, which aims to significantly improve the accuracy and reliability of at-home diagnostic tests. The funding will support expansion beyond fertility into broader women’s health and chronic condition monitoring, strengthening the role of home-based diagnostics in everyday care.
“We have always believed that healthcare should start at home. If you want to understand your hormones, you shouldn’t have to wait weeks for a lab report, you should be able to do it from home, with clinical-grade technology.”
— Aayush Rai and Varun AV, Co-founders, Inito
🔗 https://blog.inito.com/inito-raises-29m-ai-engineered-antibodies-home-diagnostics/
The FDA has expanded approval for Roche’s breast cancer diagnostic, enabling wider use of the test to guide treatment decisions and disease monitoring. The move reinforces the growing role of precision diagnostics in breast cancer care and supports more personalised treatment pathways for patients.
"With this approval, our breast diagnostic portfolio can further guide therapy decisions for clinicians, enabling a more personalised approach."
— Laura Apitz, Head of Pathology Lab, Roche Diagnostics
Enhertu, the antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, has secured another U.S. approval, expanding its use in oncology. The decision strengthens the drug’s position as a key targeted therapy and reflects continued momentum in antibody-drug conjugates for cancer treatment.
"With this approval, we are bringing enhertu to the earliest setting for HER2-positive metastatic breast cancer, where optimising efficacy has an important impact on long‑term outcomes."
— Dave Fredrickson, EVP, Oncology Haematology Business Unit, AstraZeneca
India-based nutrition startup Earthful has raised fresh capital after appearing on Shark Tank India, supporting the growth of its plant-based protein products. The brand is positioning itself at the intersection of women’s nutrition, clean ingredients and preventative health.
"While we always believed in sustainable growth, we knew that to scale our impact, we needed the right partners. When V3 Ventures and Fireside Ventures came in – together, serendipitously – it felt different. It felt right. It felt like something to be grateful for."
— Sai Sudha, Co-Founder, Earthful
A UK university spin-out has secured £3.5 million to develop technology aimed at reducing the cost and complexity of IVF treatment. The funding supports efforts to make fertility care more accessible and equitable for patients navigating assisted reproduction. The investment is led by Northern Gritstone, with support from Innovate UK Investor Partnerships Programme
“From the start, our goal was to translate our research into a real solution for patients. Thanks to the combination of grant funding and Northern Gritstone’s support, we have been able to grow our team in Leeds and take a major step toward bringing this precision-engineered IVF solution to market”
— Virginia Pensabene, Chief Executive Officer, IVFmicro ltd
The FDA has approved Sprout Pharmaceuticals' Addyi (flibanserin) for use in postmenopausal women, marking a first for women’s sexual health treatment in this population. The decision represents a notable regulatory milestone and broadens treatment options for hypoactive sexual desire disorder.
“This milestone reflects a decade of persistent work with the FDA to fundamentally change how women's sexual health is understood and prioritized. Over the years, we've pushed for the science to speak louder than the stigma — and today's approval shows how far we've come."
— Cindy Eckert, Founder and CEO, Sprout Pharmaceuticals
Another big week! Let us know what you're working on, or who we should feature next.
Email us at info@womenshealthweek.com and put "Scoop Request" as the subject!
